
1. virulence. 2016 aug 17;7(6):718-28. doi: 10.1080/21505594.2016.1195537. epub 2016
jun 3.

fr-900098, antimalarial development candidate inhibits non-mevalonate
isoprenoid biosynthesis pathway, shows evidence acute toxicity and
genotoxicity.

wiesner j(1), ziemann c(2), hintz m(3), reichenberg a(4), ortmann r(4), schlitzer
m(4), fuhst r(2), timmesfeld n(5), vilcinskas a(1)(6), jomaa h(7).

author information: 
(1)a department bioresources , fraunhofer institute molecular biology 
applied ecology ime , gießen , germany.
(2)b fraunhofer institute toxicology experimental medicine item ,
hannover , germany.
(3)c institut für laboratoriumsmedizin und pathobiochemie, molekulare diagnostik 
am standort gießen, universitätsklinikum gießen und marburg gmbh , gießen ,
germany.
(4)d institut für pharmazeutische chemie, philipps-universität marburg , marburg 
, germany.
(5)e institut für medizinische biometrie und epidemiologie, philipps-universität 
marburg , marburg , germany.
(6)f institute insect biotechnology, justus-liebig-university gießen ,
gießen , germany.
(7)g institut für laboratoriumsmedizin und pathobiochemie, molekulare diagnostik 
am standort marburg, universitätsklinikum gießen und marburg gmbh , marburg ,
germany.

fr-900098 inhibitor 1-deoxy-d-xylulose-5-phosphate (dxp)
reductoisomerase, second enzyme non-mevalonate isoprenoid biosynthesis
pathway. previous studies, fr-900098 shown possess potent antimalarial 
activity vitro murine malaria model. order provide basis 
further preclinical clinical development, studied acute toxicity and
genotoxicity fr-900098. observed acute toxicity rats, i.e. were
no clinical signs toxicity substance-related deaths the
administration single dose 3000 mg/kg body weight orally 400 mg/kg
body weight intravenously. mutagenic potential detected salmonella 
typhimurium reverse mutation assay (ames test) vitro mammalian cell gene
mutation test using mouse lymphoma l5178y/tk(+/-) cells (clone 3.7.2c), with
and without metabolic activation. addition, fr-900098 demonstrated no
clastogenic aneugenic capability significant adverse effects blood
formation vivo micronucleus test bone marrow erythrocytes nmri
mice. conclude fr-900098 lacks acute toxicity genotoxicity,
supporting development antimalarial drug.

doi: 10.1080/21505594.2016.1195537 
pmcid: pmc4991342
pmid: 27260413  [indexed medline]

